Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update

Biotech Investing

Immunomedics (NASDAQ:IMMU) reported financial results for the second quarter ended December 31, 2017. The Company also highlighted recent key progress and planned activities for its sacituzumab govitecan program. Please refer to the Company’s Quarterly Report on Form 10-Q filed today with the SEC for more details on the Company’s financial results. As quoted in the press …

Immunomedics (NASDAQ:IMMU) reported financial results for the second quarter ended December 31, 2017. The Company also highlighted recent key progress and planned activities for its sacituzumab govitecan program. Please refer to the Company’s Quarterly Report on Form 10-Q filed today with the SEC for more details on the Company’s financial results.

As quoted in the press release:

Michael Pehl, President and Chief Executive Officer, stated, “We made significant progress this quarter, taking the necessary steps to bring sacituzumab govitecan to market and achieving our vision of becoming a fully-integrated biopharmaceutical company. In December at the San Antonio Breast Cancer Symposium, we presented exciting Phase 2 results with sacituzumab govitecan, which were met with enthusiasm by clinicians around the world. The strength of the clinical profile of the sacituzumab govitecan program was recognized by Royalty Pharma, leading to an investment of $250 million and providing the necessary financial resources to carry out our strategic plan.”

Click here to read the full press release.

The Conversation (0)
×